English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 848079      Online Users : 752
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12808


    Title: Discovery of M protease inhibitors encoded by SARS-CoV-2
    Authors: Hung, HC;Ke, YY;Huang, SY;Huang, PN;Kung, YA;Chang, TY;Yen, KJ;Peng, TT;Chang, SE;Huang, CT;Tsai, YR;Wu, SH;Lee, SJ;Lin, JH;Liu, BS;Sung, WC;Shih, SR;Chen, CT;Hsu, JT
    Contributors: Institute of Biotechnology and Pharmaceutical Research;National Institute of Infectious Diseases and Vaccinology
    Abstract: The COVID-19 pandemic caused by SARS-CoV-2 is a health threat worldwide. Viral main protease (M(pro), also called 3C-like protease, 3CL(pro)) is a therapeutic target for drug discovery. Herein, we report that GC376, a broad-spectrum inhibitor targeting M(pro) in the picornavirus-like supercluster, is potent inhibitor for the M(pro) encoded by SARS-CoV-2 with half-maximum inhibitory concentration (IC(50)) of 26.4±1.1 nM. In this study, we also show that GC376 inhibits SARS-CoV-2 replication with a half-maximum effective concentration (EC(50)) of 0.91±0.03 μM. Only a small portion of SARS-CoV-2-M(pro) was covalently modified in the excess of GC376 as evaluated by mass spectrometry analysis; indicating that improved inhibitors are needed. Subsequently, molecular docking analysis revealing the recognition and binding groups of GC376 within the active site of SARS-CoV-2 M(pro) provides important new information for the optimization of GC376. Given that sufficient safety and efficacy data are available for GC376 as an investigational veterinary drug, expedited development of GC376, or its optimized analogues, for treatment of SARS-CoV-2 infection in human is recommended.
    Date: 2020-08-20
    Relation: Antimicrobial Agents and Chemotherapy. 2020 Aug 20;64(9):e00872-20.
    Link to: http://dx.doi.org/10.1128/aac.00872-20
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000566461500005
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85089786845
    Appears in Collections:[徐祖安] 期刊論文
    [陳炯東] 期刊論文
    [李秀珠] 期刊論文
    [宋旺洲] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB32669265.pdf1174KbAdobe PDF351View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback